💨 Abstract

Habib Khorakiwala, Chairman of pharma company Wockhardt, expressed concerns about potential tariffs on pharmaceutical products by the US administration, stating it would be counterproductive for Americans as India supplies 40% of prescription drugs to the US. He argued that the cost advantage and competitive pricing in India, due to lower manufacturing and research costs, would be erased if tariffs are imposed, potentially increasing costs for the American healthcare system.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖